Abstract / Description of output
A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2(+) previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival.
Original language | English |
---|---|
Pages (from-to) | 924-34 |
Number of pages | 11 |
Journal | The Oncologist |
Volume | 15 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2010 |
Keywords / Materials (for Non-textual outputs)
- Breast cancer
- Lapatinib
- Metastatic
- Capecitabine
- Survival
- HER-2